Scholarlink

<p>Neoadjuvant therapy is expanding rapidly across tumor types, yet efficacy endpoints remain anchored in subjective tumor regression grading systems developed for cytotoxic therapy. We argue that post-treatment histopathology should evolve toward quantitative and biologically interpretable metrics integrating tumor burden, immune contexture, and spatial organization. We outline a validation pathway distinguishing prognostic biomarkers from true surrogate endpoints and propose a tumor- and regimen-aware framework for developing reproducible histologic endpoints in neoadjuvant oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From tumor regression grading to interpretable endpoints in neoadjuvant oncology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Cédric Schraepen,
  • Albert Wolthuis,
  • Wentao Tang,
  • André D’Hoore,
  • Giuseppe Floris,
  • Allyson M. Peddle,
  • Xavier Sagaert,
  • Sara Verbandt,
  • Thomas McKee,
  • Inti Zlobec,
  • Jianmin Xu,
  • Sabine Tejpar,
  • Gertjan Rasschaert

摘要

Neoadjuvant therapy is expanding rapidly across tumor types, yet efficacy endpoints remain anchored in subjective tumor regression grading systems developed for cytotoxic therapy. We argue that post-treatment histopathology should evolve toward quantitative and biologically interpretable metrics integrating tumor burden, immune contexture, and spatial organization. We outline a validation pathway distinguishing prognostic biomarkers from true surrogate endpoints and propose a tumor- and regimen-aware framework for developing reproducible histologic endpoints in neoadjuvant oncology.